A new treatment being co-evaluated by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has a cleared an early-stage hurdle. The diabetes treatment, called BioChaperone Lispro U200, has successfully completed a preliminary first-phase clinical trial.
The pilot study, also conducted by France-based Adocia, aimed to determine if the treatment will accelerate the absorption of insulin lispro in healthy volunteers. Both companies signed a partnership last year for the development and commercialization of the BioChaperone Lispro programs.
“It’s important for us to research and understand ways to address the differing needs of people with diabetes,” said Thomas Hardy, M.D., Ph.D., senior director, Lilly Research Laboratories. “With these results, we are encouraged that BioChaperone Lispro may help meet these diverse needs by providing an ultra-rapid prandial insulin that could also be available as a concentrated U200 formulation.”
Adocia will receive a $10 million milestone payment from Lilly due to the successful completion of the study.